RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
29.06
-0.03 (-0.10%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close29.09
Open28.91
Bid0.00 x 0
Ask0.00 x 0
Day's Range28.91 - 29.10
52 Week Range26.30 - 32.42
Volume1,161,226
Avg. Volume1,400,665
Market Cap199.597B
Beta0.43
PE Ratio (TTM)22.95
EPS (TTM)1.27
Earnings DateN/A
Forward Dividend & Yield1.08 (3.84%)
Ex-Dividend Date2018-03-15
1y Target Est32.67
Trade prices are not sourced from all markets
  • Reuters1 hour ago

    Nikkei rises to more than 1-month high as exporters get boost from weak yen

    Japan's Nikkei share average soared to a more than one-month high on Wednesday morning as exporters such as automakers and technology firms got a boost after the dollar hit a six-month high against the ...

  • Benzinga15 hours ago

    Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...

  • Roche's Flu Drug Meets Primary Endpoint in Phase III Study
    Zacks15 hours ago

    Roche's Flu Drug Meets Primary Endpoint in Phase III Study

    Roche (RHHBY) announces that its antiviral candidate, baloxavir marboxil, met the primary endpoint in a phase III study in patients suffering from risk of complications from the flu.

  • Reuters18 hours ago

    Roche touts new flu drug as Tamiflu suffers generics hit

    Swiss drugmaker Roche's hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people at high risk of complications. Some analysts, however, have only muted expectations for the drug, baloxavir marboxil, since previously published results showed modest benefit compared to Roche's older Tamiflu medicine that is already under pressure from cheaper copies. In severe flu outbreaks, millions of people can get sick, resulting in hospital treatment and potentially hundreds of thousands of deaths, in particular among older people or those with compromised immune systems.

  • GlobeNewswire23 hours ago

    Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu

    Baloxavir marboxil - an investigational oral, single-dose antiviral - is the first flu medicine with a novel proposed mechanism of action in nearly 20 years and to demonstrate significant efficacy in high-risk ...

  • Business Wire23 hours ago

    Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu

    OTCQX: RHHBY), today announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu met the study’s primary objective, and showed superior efficacy in the primary endpoint of time to improvement of influenza symptoms versus placebo. The Centers for Disease Control and Prevention (CDC) defines people at high risk for serious flu complications to include adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, diabetes or heart disease – for these people, the flu can lead to hospitalization or even death.

  • Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis
    PR Newswire4 days ago

    Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis

    OTCQX: RHHBY) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of its Elecsys® B·R·A·H·M·S PCT™ assay to aid in antibiotic therapy decision making. "There is a global health crisis caused by the emergence and proliferation of resistant bacteria," said Dr. Alan Wright, Chief Medical Officer, Roche Diagnostics Corporation.

  • AbbVie's Imbruvica Fails in Phase III Blood Cancer Study
    Zacks6 days ago

    AbbVie's Imbruvica Fails in Phase III Blood Cancer Study

    AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.

  • Business Wire6 days ago

    Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

    OTCQX: RHHBY), today announced submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Venclexta® (venetoclax), in combination with a hypomethylating agent or in combination with low dose cytarabine (LDAC), for treatment of people with previously untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. The submission is based on the results of two Phase Ib/II studies that evaluated Venclexta in combination with azacitidine or decitabine (M14-358 study) or LDAC (M14-387 study) in this patient population.

  • Celgene Reports Positive Data on Tecentriq, Abraxane Study
    Zacks6 days ago

    Celgene Reports Positive Data on Tecentriq, Abraxane Study

    Celgene (CELG) reports positive results from a late-stage study on the combination of oncology drug, Abraxane, with immuno-oncology drug, Tecentriq, in advanced breast cancer patients.

  • Dying to Survive, China Shows the Way on Drug Prices
    Bloomberg6 days ago

    Dying to Survive, China Shows the Way on Drug Prices

    U.S. President Donald Trump exulted this week over Pfizer Inc.’s decision to delay planned drug price increases a day after he attacked the company on Twitter. He should take a look at China, where President Xi Jinping has done much better.

  • Moody's7 days ago

    Moody's: European pharma sector earnings poised to rise into 2019 as new drugs come to market

    An emerging wave of blockbuster drugs will accelerate European pharmaceutical companies' revenue growth into 2019, says Moody's Investors Service in a report published today. The rating agency's report is an update to the markets and does not constitute a rating action.

  • Drugmakers Cancel Price Hikes After California Law Takes Effect
    Bloomberg7 days ago

    Drugmakers Cancel Price Hikes After California Law Takes Effect

    A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs. The California law, which began to take effect earlier this year, requires drugmakers to give insurers, governments and drug purchasers advance notice of large price increases, as a way of publicly pressuring pharmaceutical companies to keep prices down. In the past three weeks, Novartis AG, Gilead Sciences Inc., Roche Holding AG and Novo Nordisk A/S sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs.

  • Financial Times9 days ago

    [$$] China vows to accelerate cancer drug price cuts

    China has vowed to speed up cuts to the cost of cancer drugs in a move that threatens to dent revenues in the country for multinationals such as Eli Lilly, Roche and Novartis. Officials will “accelerate price cuts” for cancer treatments, the Communist party-run People’s Daily reported over the weekend.

  • Morningstar9 days ago

    Biogen Scores Surprise Win

     Biogen BIIB and partner Eisai announced that amyloid antibody BAN2401 has yielded positive data in a large Phase 2 study in Alzheimer's disease. Biogen's strategy has its roots in the 2003 merger of Biogen (multiple sclerosis drug Avonex) and Idec (cancer drug Rituxan).

  • Alzheimer's Research Gets Glimmer of Hope, Not for First Time
    Bloomberg11 days ago

    Alzheimer's Research Gets Glimmer of Hope, Not for First Time

    For the few drugmakers that haven’t given up on the decades-long, elusive quest for a cure of Alzheimer’s disease, each piece of news is a small signpost along a possible path to success -- and billions of dollars in potential sales. This is the story of Alzheimer’s. Dramatic ups and downs have been typical, with about 200 failed attempts to find a treatment. Drugmakers are seeking to escape a maze, trying one approach, failing, then starting over with another.

  • Should Value Investors Consider Roche Holding (RHHBY) Stock?
    Zacks13 days ago

    Should Value Investors Consider Roche Holding (RHHBY) Stock?

    Let's put Roche Holding (RHHBY) stock into this equation and find out if it is a good choice for value-oriented investors right now.

  • 3 Best Biotech Acquisitions of 2018 (So Far)
    Motley Fool13 days ago

    3 Best Biotech Acquisitions of 2018 (So Far)

    There were bigger biotech deals than these this year, but arguably none better.

  • Reuters13 days ago

    Swiss bank Vontobel to cut up to 140 jobs at Notenstein La Roche

    ZURICH (Reuters) - Swiss private bank Vontobel (VONN.S) could cut up to a third of the workforce at Notenstein La Roche after it completed the takeover of its smaller rival. Vontobel could cut up to 140 ...

  • Roche's Breast Cancer Study Meets Co-Primary Endpoint
    Zacks14 days ago

    Roche's Breast Cancer Study Meets Co-Primary Endpoint

    Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

  • Moody's15 days ago

    Novartis Securities Investment Ltd -- Moody's downgrades Novartis' rating to A1; stable outlook

    Moody's Investors Service has today downgraded to A1 from Aa3 the long-term ratings of Swiss multinational pharmaceutical maker Novartis AG (Novartis) and its guaranteed subsidiaries. The outlook on the ratings is stable.

  • GlobeNewswire15 days ago

    Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash

    OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of US$ 137.00 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of 18 June 2018 among Foundation Medicine, Inc., Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, and 062018 Merger Subsidiary, Inc., a wholly owned subsidiary of Roche Holdings, Inc. The tender offer period will expire at 12am midnight, Eastern Time, at the end of the day on 30 July 2018, unless the offer is extended.

  • GlobeNewswire16 days ago

    Phase III IMpassion130 study showed Roche's Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer

    First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple ...

  • Business Wire16 days ago

    Phase III IMpassion130 Study Showed Genentech’s TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer

    – First Phase III immunotherapy study to demonstrate a statistically significant progression-free survival improvement in intention-to-treat and PD-L1 positive first-li

  • A Family Fortune Built on Cough Syrup Helps Shape a Swiss City
    Bloomberg19 days ago

    A Family Fortune Built on Cough Syrup Helps Shape a Swiss City

    The vine-covered building is home to the Paul Sacher Foundation, a research center for 20th and 21st century music whose archives include more than 100 collections of leading European musicians such as Igor Stravinsky and Bela Bartok. Its founder, the late Swiss conductor Paul Sacher, belonged to one of world’s wealthiest families: the Hoffmann-Oeri clan, whose $25.1 billion fortune is 22nd on Bloomberg’s ranking of the world’s richest dynasties. The family traces its wealth to Fritz Hoffmann-La Roche, who set up a pharmaceutical firm in Basel in 1896, producing an orange-flavored cough syrup called Sirolin.